Get the Stockscreener App
3.12
2.19%
-0.07
After Hours:
3.06
-0.06
-1.92%
Agenus Inc stock is traded at $3.12, with a volume of 804.61K.
It is down -2.19% in the last 24 hours and down -31.58% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$3.19
Open:
$3.17
24h Volume:
804.61K
Relative Volume:
1.55
Market Cap:
$106.11M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0454
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
-5.74%
1M Performance:
-31.58%
6M Performance:
-31.73%
1Y Performance:
+15.99%
1-Day Range:
$3.014
$3.23
1-Week Range:
$3.014
$3.41
52-Week Range:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.12 | 108.49M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
What valuation multiples suggest for Agenus Inc. stockFibonacci Retracement Levels & Free Unlock Hidden Market Opportunities - bollywoodhelpline.com
Agenus publishes C-800-01 trial data in The Journal for Immunotherapy of Cancer - MSN
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC - BioSpace
Agenus reports positive results for cancer immunotherapy in ovarian cancer By Investing.com - Investing.com Nigeria
Agenus Inc AJ8 Stock Analysis and ForecastVolume Analysis Techniques & High Return Investment Ideas - earlytimes.in
Botensilimab + Balstilimab in Refractory MSS mCRC: Insights from an ESMO AnalysisAgenus - Oncodaily
Agenus publishes C-800-01 trial data in The Journal for ImmunoTherapy of Cancer - TipRanks
Agenus reports positive results for cancer immunotherapy in ovarian cancer - Investing.com India
Agenus BOT and BAL data faces comparison with standard care - Traders Union
How Agenus Inc. (AJ8) stock behaves under inflation pressureEarnings Risk Report & Stepwise Trade Signal Implementation - Улправда
Can Agenus Inc. stock attract ESG capital inflows2025 Trading Recap & Technical Analysis for Trade Confirmation - ulpravda.ru
Why Agenus Inc. stock is a must watch in 2025IPO Watch & Consistent Income Trade Ideas - Улправда
Aug PreEarnings: How Agenus Inc. (AJ8) stock behaves under inflation pressureJuly 2025 Retail & Step-by-Step Trade Execution Guides - Улправда
Will Agenus Inc. (AJ8) stock benefit from Fed rate cutsEarnings Overview Summary & Low Risk High Win Rate Stock Picks - DonanımHaber
Options Flow: Will Agenus Inc. (AJ8) stock announce a stock split2025 Support & Resistance & Precise Swing Trade Alerts - Улправда
What risks investors should watch in Agenus Inc. stock2025 Major Catalysts & Technical Buy Zone Confirmations - DonanımHaber
Can Agenus Inc. stock reach $100 price targetJuly 2025 Selloffs & Risk Adjusted Buy and Sell Alerts - Улправда
Will Agenus Inc. (AJ8) stock announce a stock splitJuly 2025 Snapshot & Fast Moving Trade Plans - Улправда
What catalysts could drive Agenus Inc. stock higher2025 Trade Ideas & Fast Entry Momentum Alerts - ulpravda.ru
Is Agenus Inc. stock a good choice for value investorsJuly 2025 Catalysts & Short-Term Swing Trade Alerts - Улправда
Breakouts Watch: Is Agenus Inc. stock a good choice for value investorsJuly 2025 Movers & Weekly Momentum Stock Picks - Улправда
AGEN (Agenus) EV-to-OCF : -1.74 (As of Dec. 18, 2025) - GuruFocus
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Agenus (NASDAQ: AGEN) pays CEO Garo Armen 4,316 fully vested shares - Stock Titan
How CTLA-4 Has Re-Emerged as a Central Driver of the Next Immuno-Oncology RevolutionAgenus - Oncodaily
BOT/BAL Shows Response in Undifferentiated Pleiomorphic Sarcoma – Agenus - Oncodaily
Is Agenus Inc. (AJ8) stock testing key supportEarnings Miss & Daily Technical Stock Forecast Reports - Newser
Will Agenus Inc. (AJ8) stock sustain bullish trend into 2025Trade Risk Report & Free High Return Stock Watch Alerts - Newser
Agenus accelerates global access with BATTMAN update - Traders Union
Why Agenus Inc. (AJ8) stock fits value portfoliosBull Run & Stock Timing and Entry Methods - Newser
Transcript : Agenus Inc.Shareholder/Analyst Call - MarketScreener
Will Agenus Inc. (AJ8) stock top growth indexesRate Cut & Verified Momentum Stock Ideas - Newser
Agenus (AGEN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can Agenus Inc. stock rebound after recent weaknessJuly 2025 Weekly Recap & High Accuracy Investment Signals - Newser
Agenus Inc Stock Analysis and ForecastShort Selling Opportunities & Build Balanced Portfolio - earlytimes.in
What drives Agenus Inc AJ8 stock priceRelative Strength Index (RSI) & Superior Capital Appreciation - earlytimes.in
Free cash flow per share of Agenus Inc. – TRADEGATE:AJ8 - TradingView
Will Agenus Inc. (AJ8) stock outperform energy sector in 2025July 2025 Decliners & Reliable Volume Spike Trade Alerts - newser.com
Candlestick signals on Agenus Inc. stock today2025 Sector Review & Community Consensus Trade Alerts - newser.com
Can Agenus Inc. stock beat analyst upgradesLong Setup & Real-Time Buy Signal Notifications - newser.com
Forecasting Agenus Inc. price range with options dataEarnings Growth Summary & Technical Pattern Based Buy Signals - newser.com
Is Agenus Inc. (AJ8) stock a top dividend aristocrat candidatePortfolio Profit Report & Breakout Confirmation Alerts - newser.com
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL - BioSpace
Is Agenus Inc. stock a safe buy before earningsLong Setup & Real-Time Volume Spike Alerts - newser.com
Is Agenus Inc. stock dividend yield sustainableSell Signal & AI Enhanced Trade Execution Alerts - newser.com
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):